GI
GIFLF.US Grifols S.A
- Market cap
- USD 8.66B
- P/E
- 15.3x
- P/B
- 1.34x
- ROE
- 9.0%
- Dividend yield
- 0.74%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GIFLF.US undervalued?
Graham numberGIFLF.US trades 4.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Grifols S.A fundamental analysis
No fundamental analysis for Grifols S.A yet.
Grifols S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and mark…
Full company profileGrifols S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Grifols S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.05B | 4.32B | 4.49B | 5.10B | 5.34B | 4.93B | 6.06B | 6.59B | 7.21B | 7.52B | 7.49B |
| Gross Profit | 1.91B | 2.15B | 2.05B | 2.34B | 2.26B | 1.96B | 2.21B | 2.49B | 2.79B | 2.86B | 2.86B |
| Operating Income | 939M | 1.00B | 994M | 1.13B | 996M | 595M | 782M | 799M | 1.19B | 1.24B | 1.29B |
| EBITDA | 1.14B | 1.28B | 1.22B | 1.44B | 1.30B | 922M | 1.21B | 1.19B | 1.48B | 1.64B | 1.91B |
| Net Income | 545M | 663M | 597M | 625M | 619M | 189M | 208M | 59.3M | 157M | 402M | 519M |
| EPS | 0.80 | 0.97 | 0.87 | 0.91 | 0.90 | 0.28 | 0.31 | 0.09 | 0.22 | 0.58 | 0.76 |
| Balance Sheet | |||||||||||
| Total Assets | 10.1B | 10.9B | 12.5B | 15.5B | 15.3B | 19.2B | 21.5B | 21.4B | 21.4B | 19.7B | 20.3B |
| Total Liabilities | 6.40B | 7.29B | 7.78B | 8.70B | 8.55B | 11.1B | 13.1B | 13.5B | 12.8B | 12.1B | 12.0B |
| Shareholders' Equity | 3.72B | 3.63B | 4.23B | 4.82B | 5.11B | 5.52B | 6.13B | 5.83B | 5.88B | 5.27B | 5.79B |
| Cash & Short-term Investments | 895M | 887M | 1.03B | 2.47B | 591M | 2.68B | 591M | 646M | 1.00B | 825M | 695M |
| Total Debt | 4.89B | 6.01B | 6.29B | 7.11B | 6.91B | 10.2B | 9.75B | 11.0B | 10.1B | 9.64B | 9.37B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 553M | 842M | 737M | 569M | 1.11B | 597M | -10.9M | 208M | 902M | 1.05B | 915M |
| Capital Expenditure | 293M | 323M | 308M | 412M | 363M | 315M | 376M | 295M | 371M | 265M | 316M |
| Free Cash Flow | 261M | 519M | 430M | 157M | 748M | 282M | -386M | -87.1M | 531M | 782M | 599M |
| Ratios | |||||||||||
| ROE | 14.7% | 18.3% | 14.1% | 13.0% | 12.1% | 3.4% | 3.4% | 1.0% | 2.7% | 7.6% | 9.0% |
| ROA | 5.4% | 6.1% | 4.8% | 4.0% | 4.0% | 1.0% | 1.0% | 0.3% | 0.7% | 2.0% | 2.6% |
| Net Profit Margin | 13.5% | 15.3% | 13.3% | 12.3% | 11.6% | 3.8% | 3.4% | 0.9% | 2.2% | 5.3% | 6.9% |
| Debt to Equity | 1.31x | 1.66x | 1.49x | 1.47x | 1.35x | 1.84x | 1.59x | 1.88x | 1.71x | 1.83x | 1.62x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Grifols S.A dividends
- Dividend yield
- 0.74%
- Forward dividend
- 0.09 USD
- Payout ratio
- 31.8%
- Ex-dividend date
- Dec 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 128M | 0.19 | 31.8% |
| 2024 | EUR 962K | 0.00 | 0.6% |
| 2023 | - | - | - |
| 2022 | EUR 592K | 0.00 | 0.3% |
| 2021 | USD 259M | 0.38 | 137.2% |
| 2020 | USD 113M | 0.17 | 18.3% |
| 2019 | USD 239M | 0.35 | 38.2% |
| 2018 | USD 279M | 0.41 | 46.7% |
| 2017 | USD 218M | 0.32 | 32.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jan 4, 2016.
Who owns Grifols S.A
- Insiders 31.19%
- Institutions 41.30%
- Public & others 27.51%
- Shares outstanding 422M
- Free float 418M
Grifols S.A company profile
- Company name
- Grifols S.A
- Ticker
- GIFLF.US
- ISIN
- ES0171996087
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 25,000
- Fiscal year end
- December
- Address
- Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174
- Phone
- 34 935 71 22 00
- Website
- grifols.com
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Grifols S.A management
10- Mr. Jose Ignacio Abia BuenacheCEO & Director · born 1968
- Mr. Rahul SrinivasanChief Financial Officer · born 1977
- Mr. Lluis Pons GomezSenior Vice President of Strategy & COO Office · born 1984
- Daniel SegarraHead of Investor Relations & Sustainability and Vice President
- Mr. David Ian BellChief Corporate Affairs & Legal Officer · born 1954
- Mr. Enrique de la TorreChief Compliance Officer · born 1973
- Ms. Montse RibasChief Communications and Reputation Officer · born 1969
- Mr. Camille AlpiChief Human Resources & Talent Officer · born 1981
- Mr. Vicente Blanquer TorreChief Quality Officer · born 1961
- Mr. Ignacio Ramal SubiraChief Internal Audit & Enterprise Risk Manager · born 1968